HG Capital Trust PLC
19 December 2007
The following is the text of a press release issued by HgCapital, which manages
the investment portfolio of HgCapital Trust plc alongside those of other
institutional clients. The Trust, which is a listed investment trust giving
investors the opportunity to participate in all of HgCapital's investments, will
invest approximately €16.7million (£12m) in Casa Reha.
HgCapital acquires Casa Reha from Advent International
London, 19th December 2007: HgCapital, the European sector-focused private
equity investor, has acquired Casa Reha, one of the leading German private
nursing home groups. The transaction is subject to regulatory approval. The
company has been acquired from Advent International and management, both of
which are re-investing in the business. The value of the transaction was
undisclosed.
Casa Reha, founded in 1995 by Covenant Care International is headquartered in
Oberursel, Germany. The first nursing home was opened in 1996. Today, Casa Reha
is the country's fifth largest nursing home operator, with a nationwide
portfolio of 48 homes providing around 7,000 beds.
Contacts:
HgCapital
Philipp Schwalber Tel: +44 (0)20 7089 7888
Hering-Schuppener (German Press)
Georg Jakobs/Dennis Bader Tel: +49 (69) 92187476
Maitland (UK Press)
Peter Ogden Tel: +44 (0)20 7379 5151
Advent International
Claudia Werth Tel: +49 (69) 92037 114
About HgCapital
HgCapital is a private-equity investor in the European mid-market. We focus on
investments with an enterprise value in the range of €75-750 million. Our
business model combines sector specialisation with dedicated, pro-active support
to our portfolio companies as well as the corresponding management expertise
across all phases of the investment process. HgCapital manages more than €2.7
billion for some of the world's leading institutional and private investors. Our
goal is to achieve outstanding results for our investors, management team and
intermediaries. Further information on HgCapital can be found at
www.hgcapital.com.
HgCapital's recent transactions in the healthcare sector include:
• May 2007: sale of DocMorris to Celesio
• July 2006: sale of Castlebeck to Castle Holdings Limited for £255m
• June 2006: IPO of ClinPhone - market capitalisation of £94 million
• June 2006: Sale of Pharma Bio-Research BV (PBR) to PRA International for
£58 million
• April 2006: £322 million MBO of Paragon Healthcare
• September 2005: Sale of Tunstall for £220 million
About Advent International
Founded in 1984, Advent International is one of the world's leading global
private equity firms, with offices in 15 countries on four continents. A driving
force in international private equity for more than two decades, Advent has
built an unparalleled global platform of over 100 investment professionals
across Western and Central Europe, North America, Latin America and Asia. The
firm focuses on cross-border, strategic restructuring and growth opportunities
in five core sectors, employing a highly focused ownership approach to drive
earnings improvements in portfolio companies. Since inception, Advent has raised
£6 billion in private equity capital and completed more than 200 buyout and
private equity transactions valued at over £15 billion in 35 countries. For more
information, visit www.adventinternational.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.